Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifampridine Phosphate in MuSK-MG
NCT03304054Phase 3Completed
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Amifampridine Phosphate with Placebo (2 arms). Primary endpoint: Myasthenia Gravis-Activities of Daily Living at Day 10. Started Apr 2018; status: completed.
02
Drugs
amifampridine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03304054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304054.